News about Quest Diagnostics

On its third quarter 2026 earnings call on October 22, 2026, Quest Diagnostics (DGX) reported 10% revenue growth and raised its full-year revenue and EPS guidance. Management highlighted three points: consumer health revenue is expected to grow more than 30% through an Apple Health partnership that lets users buy, schedule and receive results for over 50 biomarkers in the app; laboratory automation and AI, under its Invigorate cost program, are helping offset wage inflation and lift margins; and proposed PAMA Medicare rate cuts could hit top-line revenue by 1% in 2027, prompting advocacy for the RESULTS Act, which has over 135 co-sponsors in Congress.